Biography

Dr. Hong brings over twenty years of experience in life science investing. She is a Co-Founder and Co-Owner of Cold Spring Bio, a boutique provider of drug discovery and investment advisory services. Previously, she was a Partner on the Ventures Investment team of Novo Holdings. Prior to Novo Holdings, Dr. Hong was a Senior Investment Director at Takeda Ventures, Inc. Prior to TVI, she was an Associate, Principal, and Partner at ProQuest Investments. She has co-founded multiple biotech companies, including Riva Therapeutics, and has served as a board director or observer on Obsidian Therapeutics, Arcellx (Nasdaq:ACLX), BioRexis Pharmaceutical Corp. (acquired by Pfizer), Gloucester Pharmaceuticals (acquired by Celgene) and LEAD Therapeutics (acquired by BioMarin), among others. Prior to joining ProQuest, Dr. Hong led numerous research projects in mammalian cancer genetics and genomics in the laboratory of Dr. Eric Lander at the Whitehead Institute for Biomedical Research.

Dr. Hong earned her PhD in Biology from the Massachusetts Institute of Technology and holds a BS in Chemistry and a BA in Molecular Biology from the University of California at Berkeley, where she graduated with honors and as a member of Phi Beta Kappa.